S4 Table. Characteristics of patients with and without statin exposure before the diagnosis of ER-positive breast cancer

	No statin (n=4,662)	Patients with statin exposure (n=659)	Total (n=5,321)	p-value
Histologic type				
IDC	3,599 (77.20)	509 (77.24)	4,108 (77.20)	0.475[a)]
ILC	236 (5.06)	40 (6.07)	276 (5.19)	
Others	827 (17.74)	110 (16.69)	937 (17.61)	
Stage: T				
T0	17 (0.36)	3 (0.46)	20 (0.38)	0.146[a)]
T1	2,344 (50.28)	354 (54.17)	2,701 (50.76)	
T2	1,611 (34.56)	226 (34.29)	1,837 (34.52)	
T3	217 (4.65)	19 (2.88)	236 (4.44)	
T4	65 (1.39)	7 (1.06)	72 (1.35)	
Tis	408 (8.75)	47 (7.13)	455 (8.55)	
Stage: N				
N0	3,154 (67.65)	454 (68.89)	3,608 (67.81)	0.023[a)]
N1	1,018 (21.84)	136 (20.64)	1,154 (21.69)	
N2	350 (7.51)	37 (5.61)	387 (7.27)	
N3	140 (3.00)	32 (4.86)	172 (3.23)	
Stage: M				
M0	4,628 (99.27)	655 (99.39)	5,283 (99.29)	> 0.999[b)]
M1	34 (0.73)	4 (0.61)	38 (0.71)	
PR				
Negative	992 (21.28)	171 (25.95)	1,163 (21.86)	0.007[a)]
Positive	3,670 (78.72)	488 (74.05)	4,158 (78.14)	
HER2				
Negative	2,242 (80.39)	331 (83.17)	2,573 (80.73)	0.189[a)]
Positive	547 (19.61)	67 (16.83)	614 (19.27)	
Age at diagnosis (yr)				

< 40	703 (15.08)	3 (0.46)	706 (13.27)	< 0.001[a]
≥ 40 and < 50	2,035 (43.65)	60 (9.10)	2,095 (39.37)	
≥ 50	1,924 (41.27)	596 (90.44)	2,520 (47.36)	
CCI				
Mean±SD	3.82±1.77	5.11±2.31	3.98±1.89	< 0.001[c]
Median (min-max)	3 (0-12)	5 (0-14)	4 (0-14)	

Values are presented as number (%). CCI, Charlson comorbidity index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; M, metastasis; N, node; PR, progesterone receptor; SD, standard deviation; T, tumor. [a]Chi-square test, [b]Fisher exact test, [c]Wilcoxon rank sum test.